Intended for healthcare professionals


Oestrogen modulator reduces risk of breast cancer

BMJ 1999; 318 doi: (Published 26 June 1999) Cite this as: BMJ 1999;318:1717
  1. Scott Gottlieb
  1. New York

    The selective oestrogen receptor modulator raloxifene, currently licensed to treat osteoporosis in postmenopausal women, significantly reduced the risk of breast cancer, according to a study published this week.

    In the three year multicentre trial 7705 women below the age of 81 years were randomised to raloxifene or placebo and followed for a median of 40 …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription